NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

OVARIAN WORKING GROUP AGENDA

EATON CHELSEA HOTEL, TORONTO, ON
ROOM: JAMES
SATURDAY MAY 3, 2014 8:00 A.M – 9:00 A.M
CHAIRS: DIANE PROVENCHER AND HELEN MACKAY

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
To review new insights in the biology of ovarian cancer
To review the landscape of clinical trials in ovarian cancer
To review study contents/clinical trial proposals in ovarian cancer
To review existing partnerships and opportunities for new partnerships in ovarian cancer

1. Closed trials
   • **OV.18** - A Randomized Trial of Concurrent Cediranib [AZD2171] (with Platinum-Based Chemotherapy) and Maintenance Cediranib in Women with Platinum-Sensitive Relapsed Ovarian Cancer
   • **OV.19** - A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin And Paclitaxel) in Patients with Epithelial Ovarian Cancer

2. Open trials
   • **OV.21** - Phase II/III Trial of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy

3. Planned Trials
   • **OV.23** – Survivac vaccine

4. Proposed Trials
   • Aspirin chemoprevention study

5. Any other business?